Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Gouty Arthritis Pipeline Drugs Market Report Overview

Gout is a type of arthritis where swelling and severe pain develops in joints, especially at the base of the big toe. Gout occurs when uric acid builds up in the blood and causes inflammation in the joints.  Symptoms include sudden onset of joint pain, joint swelling, heat in the affected area, and joint redness. Risk factors include obesity, high alcohol intake, injury to joints, long-standing kidney disease, and high intake of foods rich in purines.

The Gouty Arthritis (Gout) pipeline drugs market research report covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. The report offers details on the development of products for the treatment of Gouty Arthritis (Gout) in different stages including Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery, and Unknown.

For additional insights on gouty arthritis pipeline drugs market, https://www.globaldata.com/store/enquiry-before-buying/?report=3168230download a free report sample

Gouty Arthritis Pipeline Drugs Market Segmentation by Targets

The key targets of the gouty arthritis pipeline drugs market are Solute Carrier Family 22 Member 12, Xanthine Dehydrogenase/Oxidase, Uric Acid, Urate Transporter, Interleukin 1 Beta, Interleukin 1 Receptor, NACHT LRR And PYD Domains Containing Protein 3, Caspase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Interleukin 1 Receptor Associated Kinase 1, Interleukin 1 Receptor Associated Kinase 4, Interleukin 18 Receptor 1, Interleukin 18 Receptor Accessory Protein, Mitogen Activated Protein Kinase Kinase Kinase 7, NADPH Oxidase, Protein S100 A9, and Sphingosine 1-Phosphate Receptor 1

Gouty Arthritis Pipeline Drugs Market Analysis, by Targets

Gouty Arthritis Pipeline Drugs Market Analysis, by Targets

For more targets insights on gouty arthritis pipeline drugs market, download a free report sample

Gouty Arthritis Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of actions of the gouty arthritis pipeline drugs market are Solute Carrier Family 22 Member 12 Inhibitor, Xanthine Dehydrogenase/Oxidase Inhibitor, Uric Acid Depletor, Urate Transporter Inhibitor, Interleukin 1 Beta Inhibitor, Interleukin 1 Receptor Antagonist, NACHT LRR And PYD Domains Containing Protein 3 Inhibitor, Caspase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Interleukin 1 Receptor Associated Kinase 1 Inhibitor, Interleukin 1 Receptor Associated Kinase 4 Inhibitor, Interleukin 18 Receptor 1 Antagonist, Interleukin 18 Receptor Accessory Protein Inhibitor, Mitogen Activated Protein Kinase Kinase Kinase 7 Inhibitor, NADPH Oxidase Inhibitor, Protein S100 A9 Inhibitor, and Sphingosine 1-Phosphate Receptor 1 Agonist

Gouty Arthritis Pipeline Drugs Market Analysis, by MoA

Gouty Arthritis Pipeline Drugs Market Analysis, by MoA

For more insights on MoA, download free report sample

Gouty Arthritis Pipeline Drugs Market Segmentation by Route of Administration

The key route of administration in the gouty arthritis pipeline drugs market are oral, intramuscular, intravenous, parenteral, subcutaneous, topical, and transdermal.

Gouty Arthritis Pipeline Drugs Market Analysis, by RoA

Gouty Arthritis Pipeline Drugs Market Analysis, by RoA

For additional RoA insights on gouty arthritis pipeline drugs market, download the free report sample

Gouty Arthritis Pipeline Drugs Market Segmentation by Molecule Types

The key molecule types in the gouty arthritis pipeline drugs market include small molecule, recombinant enzyme, monoclonal antibody, recombinant protein, antisense RNAi oligonucleotide, gene-modified cell therapy, antisense oligonucleotide, biologic, enzyme, and fusion protein.

Gouty Arthritis Pipeline Drugs Market Analysis, by Molecule Types

Gouty Arthritis Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights, download free report sample

Competitive Landscape

Some of the key companies in the gouty arthritis pipeline drugs market are Fuji Yakuhin Co Ltd, Tonghua Dongbao Pharmaceutical Co Ltd, Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Acquist Theraputics Inc, C&C Research Laboratories, Fochon Pharmaceutical Ltd, Horizon Therapeutics Plc, Nippon Chemiphar Co Ltd, and Teijin Pharma Ltd.

Gouty Arthritis Pipeline Drugs Market Analysis, by Companies

Gouty Arthritis Pipeline Drugs Market Analysis, by Companies

For more information on leading companies, download a free report sample

Gouty Arthritis Pipeline Drugs Market Report Overview

Key Targets Solute Carrier Family 22 Member 12, Xanthine Dehydrogenase/Oxidase, Uric Acid, Urate Transporter, Interleukin 1 Beta, Interleukin 1 Receptor, NACHT LRR And PYD Domains Containing Protein 3, Caspase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Interleukin 1 Receptor Associated Kinase 1, Interleukin 1 Receptor Associated Kinase 4, Interleukin 18 Receptor 1, Interleukin 18 Receptor Accessory Protein, Mitogen Activated Protein Kinase Kinase Kinase 7, NADPH Oxidase, Protein S100 A9, and Sphingosine 1-Phosphate Receptor 1
Key Mechanism of Actions Solute Carrier Family 22 Member 12 Inhibitor, Xanthine Dehydrogenase/Oxidase Inhibitor, Uric Acid Depletor, Urate Transporter Inhibitor, Interleukin 1 Beta Inhibitor, Interleukin 1 Receptor Antagonist, NACHT LRR And PYD Domains Containing Protein 3 Inhibitor, Caspase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Interleukin 1 Receptor Associated Kinase 1 Inhibitor, Interleukin 1 Receptor Associated Kinase 4 Inhibitor, Interleukin 18 Receptor 1 Antagonist, Interleukin 18 Receptor Accessory Protein Inhibitor, Mitogen Activated Protein Kinase Kinase Kinase 7 Inhibitor, NADPH Oxidase Inhibitor, Protein S100 A9 Inhibitor, and Sphingosine 1-Phosphate Receptor 1 Agonist
Key Routes of Administration Oral, Intramuscular, Intravenous, Parenteral, Subcutaneous, Topical, and Transdermal
Key Molecule Types Small Molecule, Recombinant Enzyme, Monoclonal Antibody, Recombinant Protein, Antisense RNAi Oligonucleotide, Gene-Modified Cell Therapy, Antisense Oligonucleotide, Biologic, Enzyme, and Fusion Protein
Leading Companies Fuji Yakuhin Co Ltd, Tonghua Dongbao Pharmaceutical Co Ltd, Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Acquist Theraputics Inc, C&C Research Laboratories, Fochon Pharmaceutical Ltd, Horizon Therapeutics Plc, Nippon Chemiphar Co Ltd, and Teijin Pharma Ltd

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gouty Arthritis (Gout) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Gouty Arthritis (Gout) (Musculoskeletal Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gouty Arthritis (Gout) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gouty Arthritis (Gout) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.

3SBio Inc
Aclaris Therapeutics Inc
Acquist Theraputics Inc
Akaal Pharma Pty Ltd
Allena Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Aqilion AB
Arrowhead Pharmaceuticals Inc
Arthrosi Therapeutics Inc
C&C Research Laboratories
Deep Genomics Inc
DevaCell Inc
Dianomi Therapeutics Inc
Dyve Biosciences Inc
Enzychem Lifesciences Corp
EryDel SpA
Fochon Pharmaceutical Ltd
FortuneRock (China) Ltd
Fuji Yakuhin Co Ltd
GeneScience Pharmaceuticals Co Ltd
Hangzhou Grand Biologic Pharmaceutical Inc
Hinova Pharmaceuticals Co Ltd
Horizon Therapeutics Plc
IcanoMAB GmbH
InflammatoRx inc
InventisBio Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
LG Chem Ltd
Nippon Chemiphar Co Ltd
Olatec Therapeutics LLC
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Protalix BioTherapeutics Inc
Rigel Pharmaceuticals Inc
Shanghai Junshi Bioscience Co Ltd
Shanghai Yingli Pharmaceutical Co Ltd
Shanton Pharma Co Ltd
Stealth Biologics LLC
Synlogic Inc
TaiwanJ Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Tonghua Dongbao Pharmaceutical Co Ltd
TWi Biotechnology Inc
Usynova Pharmaceuticals Ltd
Wellstat Therapeutics Corp
West Lake Biomedical Technology (Hangzhou) Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gouty Arthritis (Gout) – Overview

Gouty Arthritis (Gout) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gouty Arthritis (Gout) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gouty Arthritis (Gout) – Companies Involved in Therapeutics Development

Gouty Arthritis (Gout) – Drug Profiles

Gouty Arthritis (Gout) – Dormant Projects

Gouty Arthritis (Gout) – Discontinued Products

Gouty Arthritis (Gout) – Product Development Milestones

Featured News & Press Releases

Aug 09, 2022: Arthrosi completes AR882 renal impairment study

Aug 03, 2022: LG Chem enters final stage of clinical development for new gout drug

Jul 19, 2022: Allena pharmaceuticals announces completion of enrollment of cohorts A and B of ALLN-346 phase 2a study 202 in patients with Gout and stages 2 and 3 chronic kidney disease

Jun 16, 2022: Atom Bioscience to update clinical development of new drug to treat gout at BIO International Convention, June 13 – 16, 2022, San Diego, CA

Jun 13, 2022: Selecta Biosciences announces partnership advancements and clinical trial updates

Jun 02, 2022: Dyve Biosciences announces phase 2 TARGETS study of DYV702 for pain associated with acute gout flares showcased in podium presentation at 2022 EULAR congress

May 31, 2022: Fortress Biotech announces first patient dosed in phase 1 clinical trial evaluating dotinurad for the treatment of gout in the United States

Mar 21, 2022: Atom Bioscience announces positive phase 2a results for investigational new drug to treat chronic gout

Mar 15, 2022: The Phase I clinical trial of Eusen Jianheng’s new gout drug UA007 was successfully completed

Dec 14, 2021: Arthrosi Therapeutics announces patient enrollment in global phase 2b study of AR882

Dec 02, 2021: Sobi and Selecta Biosciences complete enrolment for gout therapy trial

Nov 15, 2021: Dyve Biosciences hosting key opinion leader webinar on Gout and DYV702

Nov 08, 2021: Shanghai Fosun Pharmaceutical (Group) announcement in relation to the approval for Clinical Trial regarding Investigational New Drug of a subsidiary

Nov 03, 2021: Allena Pharmaceuticals receives Fast Track Designation from FDA for the Development of ALLN-346 for chronic treatment of hyperuricemia in patients with gout and advanced chronic kidney disease

Nov 02, 2021: Arthrosi presents AR882 posters at ACR 2021

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Gouty Arthritis (Gout), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Gouty Arthritis (Gout) – Dormant Projects, 2022

Gouty Arthritis (Gout) – Dormant Projects, 2022 (Contd..1)

Gouty Arthritis (Gout) – Dormant Projects, 2022 (Contd..2)

Gouty Arthritis (Gout) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Gouty Arthritis (Gout), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets of the gouty arthritis pipeline drugs market?

    The key targets of the gouty arthritis pipeline drugs market are Solute Carrier Family 22 Member 12, Xanthine Dehydrogenase/Oxidase, Uric Acid, Urate Transporter, Interleukin 1 Beta, Interleukin 1 Receptor, NACHT LRR And PYD Domains Containing Protein 3, Caspase 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 2, Interleukin 1 Receptor Associated Kinase 1, Interleukin 1 Receptor Associated Kinase 4, Interleukin 18 Receptor 1, Interleukin 18 Receptor Accessory Protein, Mitogen Activated Protein Kinase Kinase Kinase 7, NADPH Oxidase, Protein S100 A9, and Sphingosine 1-Phosphate Receptor 1.

  • What are the key mechanism of actions of the gouty arthritis pipeline drugs market?

    The key mechanism of actions of the gouty arthritis pipeline drugs market are Solute Carrier Family 22 Member 12 Inhibitor, Xanthine Dehydrogenase/Oxidase Inhibitor, Uric Acid Depletor, Urate Transporter Inhibitor, Interleukin 1 Beta Inhibitor, Interleukin 1 Receptor Antagonist, NACHT LRR And PYD Domains Containing Protein 3 Inhibitor, Caspase 1 Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor, Interleukin 1 Receptor Associated Kinase 1 Inhibitor, Interleukin 1 Receptor Associated Kinase 4 Inhibitor, Interleukin 18 Receptor 1 Antagonist, Interleukin 18 Receptor Accessory Protein Inhibitor, Mitogen Activated Protein Kinase Kinase Kinase 7 Inhibitor, NADPH Oxidase Inhibitor, Protein S100 A9 Inhibitor, and Sphingosine 1-Phosphate Receptor 1 Agonist

  • What are the key routes of administration in the gouty arthritis pipeline drugs market?

    The key route of administration in the gouty arthritis pipeline drugs market are oral, intramuscular, intravenous, parenteral, subcutaneous, topical, and transdermal.

  • What are the key molecule types in the gouty arthritis pipeline drugs market?

    The key molecule types in the gouty arthritis pipeline drugs market include small molecule, recombinant enzyme, monoclonal antibody, recombinant protein, antisense RNAi oligonucleotide, gene-modified cell therapy, antisense oligonucleotide, biologic, enzyme, and fusion protein.

  • Which are the leading companies in the gouty arthritis pipeline drugs market?

    Some of the key companies in the gouty arthritis pipeline drugs market are Fuji Yakuhin Co Ltd, Tonghua Dongbao Pharmaceutical Co Ltd, Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Acquist Theraputics Inc, C&C Research Laboratories, Fochon Pharmaceutical Ltd, Horizon Therapeutics Plc, Nippon Chemiphar Co Ltd, and Teijin Pharma Ltd.

Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Gouty Arthritis (Gout) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.